Taimour Y Langaee1, Guo Zhong, Wenjun Li, Issam Hamadeh, Mohamed Hassan M Solayman, Caitrin W McDonough, Peter W Stacpoole, Margaret O James. 1. aDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy bDepartment of Medicinal Chemistry, College of Pharmacy cDepartment of Medicine, College of Medicine dDepartment of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA eDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Abstract
BACKGROUND/ OBJECTIVES: The zeta-1 family isoform of GST biotransforms the investigational drug dichloroacetate (DCA) and certain other halogenated carboxylic acids. Haplotype variability in GSTZ1 influences the kinetics and, possibly, the toxicity of DCA. DCA metabolism correlates with expression of the GSTZ1 protein, so it is important to document variables that affect expression. Following up on a limited previous study, we tested the hypothesis that a coding single nucleotide polymorphism (SNP), the lysine (K) amino acid (E32>K) in GSTZ1 haplotypes linked to a promoter region SNP results in lower hepatic expression of GSTZ1. MATERIALS AND METHODS: The influence of K carrier and non-K carrier haplotypes on GSTZ1 expression was determined by analyzing 78 liver samples from individuals aged 7-84 years of various racial and ethnic backgrounds. GSTZ1 expression data were analyzed on the basis of the presence or absence of lysine 32. RESULTS: GSTZ1 protein expression differed significantly between K carrier and non-K carrier haplotypes (P=0.001) in Whites, but not in African-Americans (P=0.277). We attribute this difference in GSTZ1 expression among K carrier haplotypes in Whites to the linkage disequilibrium between the K or A allele from the G>A SNP (rs7975), within the promoter G>A-1002 SNP (rs7160195) A allele. There is no linkage disequilibrium between these two polymorphisms in African-Americans. CONCLUSION: We conclude that the lower expression of GSTZ1 in Whites who possess the K carrier haplotype results in lower enzymatic activity and slower metabolism of DCA, compared with those who possess the non-K carrier haplotype. These results further define safe, genetics-based dosing regimens for chronic DCA administration.
BACKGROUND/ OBJECTIVES: The zeta-1 family isoform of GST biotransforms the investigational drug dichloroacetate (DCA) and certain other halogenated carboxylic acids. Haplotype variability in GSTZ1 influences the kinetics and, possibly, the toxicity of DCA. DCA metabolism correlates with expression of the GSTZ1 protein, so it is important to document variables that affect expression. Following up on a limited previous study, we tested the hypothesis that a coding single nucleotide polymorphism (SNP), the lysine (K) amino acid (E32>K) in GSTZ1 haplotypes linked to a promoter region SNP results in lower hepatic expression of GSTZ1. MATERIALS AND METHODS: The influence of K carrier and non-K carrier haplotypes on GSTZ1 expression was determined by analyzing 78 liver samples from individuals aged 7-84 years of various racial and ethnic backgrounds. GSTZ1 expression data were analyzed on the basis of the presence or absence of lysine 32. RESULTS:GSTZ1 protein expression differed significantly between K carrier and non-K carrier haplotypes (P=0.001) in Whites, but not in African-Americans (P=0.277). We attribute this difference in GSTZ1 expression among K carrier haplotypes in Whites to the linkage disequilibrium between the K or A allele from the G>A SNP (rs7975), within the promoter G>A-1002 SNP (rs7160195) A allele. There is no linkage disequilibrium between these two polymorphisms in African-Americans. CONCLUSION: We conclude that the lower expression of GSTZ1 in Whites who possess the K carrier haplotype results in lower enzymatic activity and slower metabolism of DCA, compared with those who possess the non-K carrier haplotype. These results further define safe, genetics-based dosing regimens for chronic DCA administration.
Authors: Albert L Shroads; Taimour Langaee; Bonnie S Coats; Tracie L Kurtz; John R Bullock; David Weithorn; Yan Gong; David A Wagner; David A Ostrov; Julie A Johnson; Peter W Stacpoole Journal: J Clin Pharmacol Date: 2011-06-03 Impact factor: 3.126
Authors: Xu Guo; Vaishali Dixit; Huiping Liu; Albert L Shroads; George N Henderson; Margaret O James; Peter W Stacpoole Journal: Drug Metab Dispos Date: 2005-09-30 Impact factor: 3.922
Authors: R Cornett; M O James; G N Henderson; J Cheung; A L Shroads; P W Stacpoole Journal: Biochem Biophys Res Commun Date: 1999-09-07 Impact factor: 3.575
Authors: Wenjun Li; Yuan Gu; Margaret O James; Ronald N Hines; Pippa Simpson; Taimour Langaee; Peter W Stacpoole Journal: Drug Metab Dispos Date: 2011-10-25 Impact factor: 3.922
Authors: Gonçalo R Abecasis; David Altshuler; Adam Auton; Lisa D Brooks; Richard M Durbin; Richard A Gibbs; Matt E Hurles; Gil A McVean Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Stephan C Jahn; Lauren A Gay; Claire J Weaver; Rolf Renne; Taimour Y Langaee; Peter W Stacpoole; Margaret O James Journal: Drug Metab Dispos Date: 2020-05-01 Impact factor: 3.922
Authors: Guo Zhong; Margaret O James; Marci G Smeltz; Stephan C Jahn; Taimour Langaee; Pippa Simpson; Peter W Stacpoole Journal: Drug Metab Dispos Date: 2018-05-31 Impact factor: 3.922
Authors: Margaret O James; Stephan C Jahn; Guo Zhong; Marci G Smeltz; Zhiwei Hu; Peter W Stacpoole Journal: Pharmacol Ther Date: 2016-10-19 Impact factor: 12.310
Authors: Stephan C Jahn; Mohamed Hassan M Solayman; Ryan J Lorenzo; Taimour Langaee; Peter W Stacpoole; Margaret O James Journal: Biochim Biophys Acta Date: 2016-02-02
Authors: Dan Dan Tian; Samuel K Bennett; Lucy A Coupland; Kathryn Forwood; Yadanar Lwin; Niloofar Pooryousef; Illa Tea; Thy T Truong; Teresa Neeman; Philip Crispin; James D'Rozario; Anneke C Blackburn Journal: Pharmacol Res Perspect Date: 2019-10-08